[go: up one dir, main page]

MX2013011591A - Métodos y composiciones para tratar enfermedades neurodegenerativas. - Google Patents

Métodos y composiciones para tratar enfermedades neurodegenerativas.

Info

Publication number
MX2013011591A
MX2013011591A MX2013011591A MX2013011591A MX2013011591A MX 2013011591 A MX2013011591 A MX 2013011591A MX 2013011591 A MX2013011591 A MX 2013011591A MX 2013011591 A MX2013011591 A MX 2013011591A MX 2013011591 A MX2013011591 A MX 2013011591A
Authority
MX
Mexico
Prior art keywords
compositions
methods
neurodegenerative diseases
treating neurodegenerative
treating
Prior art date
Application number
MX2013011591A
Other languages
English (en)
Inventor
William C Shakespeare
Frank G Haluska
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of MX2013011591A publication Critical patent/MX2013011591A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención describe métodos y composiciones para tratar o prevenir una enfermedad neurodegenerativa, mediante la administración de un compuesto de la Fórmula I: o una sal, solvato o hidrato farmacéuticamente aceptable del mismo, en donde las variables son tal como se define en la presente invención.
MX2013011591A 2011-04-07 2012-04-06 Métodos y composiciones para tratar enfermedades neurodegenerativas. MX2013011591A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472961P 2011-04-07 2011-04-07
US201161518427P 2011-05-05 2011-05-05
PCT/US2012/032566 WO2012139027A1 (en) 2011-04-07 2012-04-06 Methods and compositions for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
MX2013011591A true MX2013011591A (es) 2014-04-14

Family

ID=46969573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011591A MX2013011591A (es) 2011-04-07 2012-04-06 Métodos y composiciones para tratar enfermedades neurodegenerativas.

Country Status (11)

Country Link
US (1) US20140045826A1 (es)
EP (1) EP2694064A1 (es)
JP (1) JP2014510154A (es)
KR (1) KR20140022063A (es)
CN (1) CN103582478A (es)
AU (1) AU2012240026A1 (es)
BR (1) BR112013024171A2 (es)
CA (1) CA2832483A1 (es)
EA (1) EA201391485A1 (es)
MX (1) MX2013011591A (es)
WO (1) WO2012139027A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343042B (es) 2005-12-23 2016-10-21 Ariad Pharma Inc Compuestos heteroarilicos biciclicos.
WO2013170774A1 (zh) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
CA2815506C (en) 2012-12-12 2018-12-11 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2013204506B2 (en) * 2012-12-13 2016-05-05 Takeda Pharmaceuticals U.S.A., Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US20140343282A1 (en) 2013-05-16 2014-11-20 Apicore, Llc Processes for making ponatinib and intermediates thereof
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
WO2015085971A1 (en) * 2013-12-09 2015-06-18 Zentiva, K.S. Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
CN104496994B (zh) * 2014-01-06 2016-12-07 广东东阳光药业有限公司 一种炔类杂芳基化合物的新晶型
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
CN106146391A (zh) 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
CN109641893B (zh) * 2016-06-20 2021-07-20 大邱庆北尖端医疗产业振兴财团 新的咪唑并吡啶衍生物及其制备方法和用途
JP7158383B2 (ja) * 2016-12-15 2022-10-21 アリアド ファーマシューティカルズ， インコーポレイテッド Ｃ－ｋｉｔ阻害剤としてのベンズイミダゾール化合物
CN108399315B (zh) * 2018-03-01 2022-02-22 中国科学院长春应用化学研究所 一种Bcr-Abl蛋白激酶抑制剂的筛选方法
SG11202012922VA (en) 2018-07-09 2021-01-28 Boehringer Ingelheim Animal Health Usa Inc Anthelminthic heterocyclic compounds
US11746110B2 (en) 2018-07-17 2023-09-05 Shenzhen Targetrx, Inc. Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity
CA3133100A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
WO2020223235A1 (en) * 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CA3142899A1 (en) 2019-06-11 2020-12-17 Sun Pharma Advanced Research Company Ltd. Treatment for synucleinopathies
CR20220665A (es) 2020-05-29 2023-07-19 Boehringer Ingelheim Pharma Compuestos heterocíclicos como anthelmínticos
GB202019874D0 (en) * 2020-12-16 2021-01-27 Benevolentai Bio Ltd New compounds and methods
EP4326269A4 (en) * 2021-04-19 2025-08-20 Univ Oregon Health & Science Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative disorders
PE20250675A1 (es) 2021-11-01 2025-03-04 Boehringer Ingelheim Vetmedica Gmbh Compuestos de pirrolopiridazina como antihelminticos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248168A1 (en) * 2003-03-25 2004-12-09 Wei Liu Novel brain-localized protein kinases homologous to homeodomain-interacting protein kinases
MX343042B (es) * 2005-12-23 2016-10-21 Ariad Pharma Inc Compuestos heteroarilicos biciclicos.

Also Published As

Publication number Publication date
KR20140022063A (ko) 2014-02-21
CN103582478A (zh) 2014-02-12
JP2014510154A (ja) 2014-04-24
CA2832483A1 (en) 2012-10-11
US20140045826A1 (en) 2014-02-13
BR112013024171A2 (pt) 2016-12-13
EP2694064A1 (en) 2014-02-12
AU2012240026A1 (en) 2013-09-19
WO2012139027A1 (en) 2012-10-11
EA201391485A1 (ru) 2014-03-31

Similar Documents

Publication Publication Date Title
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX2011009796A (es) Inhibidores de la cinasa pi3.
PH12019500480A1 (en) Pyridine compound
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MY176488A (en) 1, 4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
MY199131A (en) Human plasma kallikrein inhibitors
PH12017501426A1 (en) Derivatives of betulin
NZ712207A (en) Tetrahydropyrrolothiazine compounds
IN2014KN00948A (es)
MY176126A (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
MX349159B (es) Derivados deuterados de ivacaftor.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
PH12018500061A1 (en) Oxysterols and methods of use thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
HK1205506A1 (en) Protein kinase inhibitors
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
WO2013074905A3 (en) Compounds, compositions, pharmaceutical compositions, and methods of use
TN2011000507A1 (en) Inhibitors of pi3 kinase and / or mtor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal